Insulet Unveils Initiatives for National Diabetes Awareness Month and World Diabetes Day

Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology through its Omnipod® products, has announced its plans to celebrate National Diabetes Awareness Month and World Diabetes Day with a variety of activities throughout November. Insulet Corporation (NASDAQ:…

Read MoreInsulet Unveils Initiatives for National Diabetes Awareness Month and World Diabetes Day

Arrowhead Launches ‘We’ll Get There Soon’ Campaign for Rare Disease Awareness

On FCS Awareness Day, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced the launch of its new disease awareness campaign, “We’ll Get There Soon,” aimed at providing hope to the community affected by Familial Chylomicronemia Syndrome (FCS). The campaign focuses on raising…

Read MoreArrowhead Launches ‘We’ll Get There Soon’ Campaign for Rare Disease Awareness

Siemens Healthineers to Automate Patient Testing, Improving Lab Workflow and Staffing

Siemens Healthineers is introducing a new solution that consolidates 25 tasks traditionally performed manually by clinical laboratory staff, reducing manual workflow steps by 75%. This innovation redefines automation in clinical labs. Conventional total laboratory automation relies on tracks to transport…

Read MoreSiemens Healthineers to Automate Patient Testing, Improving Lab Workflow and Staffing

Avantect Pancreatic Cancer Test Cost-Effective for High-Risk Diabetes Patients

ClearNote Health, focused on early cancer detection, has announced findings from a cost-effectiveness analysis of the Avantect Pancreatic Cancer test for managing new-onset diabetes (NOD) patients. This analysis, conducted with the Mayo Clinic and Arizona Centers for Digestive Health, will…

Read MoreAvantect Pancreatic Cancer Test Cost-Effective for High-Risk Diabetes Patients

BMS Shares Long-term EMERGENT Data on COBENFY™ for Schizophrenia at Psych Congress 2024

Bristol Myers Squibb (NYSE: BMY) has announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials, which assessed the long-term efficacy, safety, and tolerability of COBENFY™ (xanomeline and trospium chloride) in adults with schizophrenia over 52 weeks…

Read MoreBMS Shares Long-term EMERGENT Data on COBENFY™ for Schizophrenia at Psych Congress 2024

BlueWind Medical Research: Revi® System Offers Effective Alternative to SNM for Overactive Bladder

BlueWind Medical, Ltd., a leader in implantable Tibial Neuromodulation (iTNM) and the developer of the Revi® System for urge urinary incontinence (UUI), has announced the publication of a comprehensive meta-analysis in the October issue of Advances in Therapy. Titled “Sacral…

Read MoreBlueWind Medical Research: Revi® System Offers Effective Alternative to SNM for Overactive Bladder